At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
BI 10773 XX (Trial Formulation 2) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Relative Bioavailability of 25 mg BI 10773 (Final Formulation) Compared to 25 mg BI 10773 XX (Trial Formulation 2) Following Oral Administration in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)
In Brief
A Phase 1 clinical trial evaluating BI 10773 XX (Trial Formulation 2) and BI 10773 (Final Formulation) for Healthy. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The objective of the study is to investigate the relative bioavailability of the final tablet formulation (FF) of BI 10773 in comparison to the tablet formulation 2 (TF2).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedNov 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedNov 16, 2010
Enrollment StartNov 1, 2010
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 15.6 years ago
Interventions
BI 10773 XX (Trial Formulation 2)drug
one single dose tablet in the morning
BI 10773 (Final Formulation)drug
one single film-coated tablet in the morning